Q1 EPS Estimates for Globus Medical Lifted by Zacks Research

Globus Medical, Inc. (NYSE:GMED) – Analysts at Zacks Research boosted their Q1 2026 EPS estimates for shares of Globus Medical in a research report issued on Thursday, April 23rd. Zacks Research analyst Team now expects that the medical device company will post earnings of $0.90 per share for the quarter, up from their prior forecast of $0.89. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $4.46 per share. Zacks Research also issued estimates for Globus Medical’s Q1 2027 earnings at $1.09 EPS, Q4 2027 earnings at $1.25 EPS, FY2027 earnings at $4.70 EPS, Q1 2028 earnings at $1.22 EPS and FY2028 earnings at $5.27 EPS.

Globus Medical (NYSE:GMED) last announced its earnings results on Tuesday, February 24th. The medical device company reported $1.28 EPS for the quarter, beating analysts’ consensus estimates of $1.06 by $0.22. The business had revenue of $826.42 million for the quarter, compared to analysts’ expectations of $803.29 million. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. The company’s quarterly revenue was up 25.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.84 EPS.

A number of other equities analysts have also weighed in on the stock. Truist Financial set a $115.00 price objective on shares of Globus Medical in a research report on Wednesday, February 25th. Needham & Company LLC lifted their price objective on shares of Globus Medical from $112.00 to $114.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Barclays lifted their price objective on shares of Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Piper Sandler reiterated an “overweight” rating and issued a $115.00 price objective (up from $90.00) on shares of Globus Medical in a research report on Thursday, January 8th. Finally, TD Cowen upgraded shares of Globus Medical to a “strong-buy” rating in a research report on Tuesday, January 27th. Three investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, Globus Medical presently has a consensus rating of “Moderate Buy” and an average target price of $104.36.

Globus Medical Price Performance

Shares of Globus Medical stock opened at $95.05 on Friday. The firm’s fifty day simple moving average is $90.00 and its 200-day simple moving average is $84.76. The stock has a market capitalization of $12.86 billion, a price-to-earnings ratio of 24.12, a PEG ratio of 2.20 and a beta of 1.09. Globus Medical has a 12 month low of $51.79 and a 12 month high of $101.40.

Insiders Place Their Bets

In related news, EVP Kelly Huller sold 20,000 shares of Globus Medical stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total value of $1,890,000.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 18.51% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Globus Medical

Institutional investors have recently made changes to their positions in the stock. Advisory Services Network LLC purchased a new stake in shares of Globus Medical during the 3rd quarter worth $26,000. EverSource Wealth Advisors LLC boosted its position in shares of Globus Medical by 74.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after purchasing an additional 197 shares in the last quarter. SBI Securities Co. Ltd. boosted its position in shares of Globus Medical by 98.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after purchasing an additional 167 shares in the last quarter. First Horizon Corp purchased a new stake in shares of Globus Medical during the 3rd quarter worth $31,000. Finally, Parallel Advisors LLC boosted its position in shares of Globus Medical by 45.1% during the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after purchasing an additional 173 shares in the last quarter. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.